Cancer Research Targets  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takamizawa, J.
Right arrow Articles by Takahashi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takamizawa, J.
Right arrow Articles by Takahashi, T.
[Cancer Research 64, 3753-3756, June 1, 2004]
© 2004 American Association for Cancer Research


Advances in Brief

Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival

Junichi Takamizawa1,4, Hiroyuki Konishi1, Kiyoshi Yanagisawa1, Shuta Tomida1, Hirotaka Osada1, Hideki Endoh3, Tomoko Harano1, Yasushi Yatabe2, Masato Nagino4, Yuji Nimura4, Tetsuya Mitsudomi3 and Takashi Takahashi1

1 Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan; Departments of 2 Anatomic and Molecular Diagnostic Pathology and 3 Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan; 4 Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan


    ABSTRACT
 Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
In this study, we report for the first time reduced expression of the let-7 microRNA in human lung cancers. Interestingly, 143 lung cancer cases that had undergone potentially curative resection could be classified into two major groups according to let-7 expression in unsupervised hierarchical analysis, showing significantly shorter survival after potentially curative resection in cases with reduced let-7 expression (P = 0.0003). Multivariate COX regression analysis showed this prognostic impact to be independent of disease stage (hazard ratio = 2.17; P = 0.009). In addition, overexpression of let-7 in A549 lung adenocarcinoma cell line inhibited lung cancer cell growth in vitro. This study represents the first report of reduced expression of let-7 and the potential clinical and biological effects of such a microRNA alteration.


    Introduction
 Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
Cells contain a variety of noncoding RNAs, which perform a multitude of functions. Recently, microRNAs (miRNAs), an abundant class of small noncoding RNAs of about 22 nucleotides in length, have been recognized as being numerous and phylogenetically well conserved (1) . The miRNA species are encoded by genes that are presumably transcribed into single or clustered miRNA precursors, which are converted to mature forms of miRNAs through stepwise processing including generation of ~70 nucleotide pre-miRNA with a characteristic hairpin structure from the longer nascent transcripts (pri-miRNA) and the following Dicer-mediated processing into mature forms (2, 3, 4, 5) . Although thus far over 300 miRNA genes have been discovered in various organisms (6, 7, 8, 9, 10) , including humans, their precise physiological functions are largely unknown except for a handful of miRNAs (11, 12, 13, 14, 15, 16, 17) , and their potential pathological involvement including oncogenesis is yet to be explored.

The Caenorhabditis elegans let-7miRNA is to date the best-studied example along with lin-4 of the same worm (11, 12, 13, 14, 15) , both of which were initially identified by genetic analysis of the developmental timing defects of mutants. The let-7 miRNA, which starts to be expressed during the late developmental stage, acts as a post-transcriptional repressor of lin-41, hbl-1/lin-57 and perhaps other genes that contain sequences imprecisely complementary to the miRNA in their 3' untranslated regions. The expression levels of the human let-7 gene have been shown to vary among various adult tissues, lung being one of the tissues with most abundant expression of let-7 (18) .

In this study, we show for the first time that expression levels of let-7 are frequently reduced in lung cancers both in vitro and in vivo. Furthermore, lung cancer patients with reduced let-7 expression were found to have significantly worse prognosis after potentially curative resection, and this prognostic impact of reduced let-7 expression appears to be independent of disease stage in multivariate COX regression analysis. In addition, we show that overexpression of let-7 inhibits growth of lung cancer cells in vitro.


    Materials and Methods
 Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
Study Population.
This study dealt with 159 nonsmall cell lung carcinoma (NSCLC) tissue specimens collected with the approval of the institutional review board of the Aichi Cancer Center. The specimens from 143 cases (105 adenocarcinomas, 25 squamous cell carcinomas, 9 large cell carcinomas, and 4 adenosquamous cell carcinomas), which had been followed up for >5 years after potentially curative resection, were used specifically for studying the prognostic significance of let-7. These 143 cases consisted of 90 female and 53 male patients with a median age of 62 (range, 32–84), and with 75 in stage I, 19 in stage II, and 49 in stage III.

Preparation of Cell Line and Tissue Samples.
All of the human NSCLC cell lines analyzed were cultured with 5% (v/v) FCS-containing RPMI 1640 at 37°C with 5% CO2. BEAS-2B and HPL1D (19) cells were cultured with 1% (v/v) FCS-containing Ham’s F-12 supplemented with bovine insulin (5 µg/ml), human transferrin (5 µg/ml), 10–7 M hydrocortisone, 2 x 10–10 M triiode thyronine, penicillin (100 IU/ml), and streptomycin (100 µg/ml) at 37°C with 5% CO2. The tumor specimens were homogenized in guanidine isothiocyanate homogenization buffer immediately after resection and stored at –30°C until use with the approval of the institutional review board. Processing of all cell lines and tissue samples for RNA extraction were performed according to the standard procedures.

Northern Blotting.
Ten µg of RNA were separated on a 15% denaturing polyacrylamide gel. The RNA was then transferred to Zeta-Probe GT Blotting Membranes electrophoretically overnight. Probes (let-7; 5'-TACTATACAACCTACTACCTCAATTTGCC and 5S; 5'-TTAGCTTCCGAGATCAGACGA) were generated by T4 polynucleotide kinase (New England Biolabs, Beverly, MA) mediated end-labeling of DNA oligonucleotides with [{gamma}-32P]ATP. Prehybridization and hybridization were carried out using hybridization buffer (0.25 M sodium phosphate (pH 7.2), 7% SDS, 0.5% sodium PPI). The most stringent wash was carried out in 2x SSC and 1% SDS at 37.5°C.

Real-Time Reverse Transcription-PCR.
Real-time reverse transcription-PCR was performed using an ABI Prism 7900 Sequence Detection System (Perkin-Elmer Applied Biosystems, Foster City, CA), the SYBR Green PCR Master Mix (Perkin-Elmer Applied Biosystems), and random-primed cDNAs (corresponding to 20 ng of total RNA extracted from tissue samples).

The primer pairs used were let-7a-1S (sense; 5'-CCTGGATGTTCTCTTCACTG) and let-7a-1AS (antisense; 5'-GCCTGGATGCAGACTTTTCT); let-7a-2S (sense; 5'-TTCCAGCCATTGTGACTGCA) and let-7a-2AS (antisense; 5'-CTCACCATGTTGTTTAGTGC); let-7a-3S (sense; 5'-ACCAAGACCGACTGCCCTTT) and let-7a-3AS (antisense; 5'-CTCTGTCCACCGCAGATATT); let-7f-1S (sense; 5'-TGTACTTTCCATTCCAGAAG) and let-7f-1AS (antisense; 5'-TAATGCAGCAAGTCTACTCC); let-7f-2S (sense; 5'-TGAAGATGGACACTGGTGCT) and let-7f-2AS (antisense; 5'-CAGTCGGAGAAGAAGTGTAC); and 5S–S (sense; 5'-TACGGCCATACCACCCTGAA) and 5S-AS (antisense; 5'-TAACCAGGCCCGACCCTGCT). To quantify the expression level of the let-7 genes, standard curves were made using serially diluted pBluescriptIISK (–) inserted with each PCR product into the EcoRV site. PCR amplification consisted of 55 cycles (95°C for 30 s, 56°C to 60°C optimized for each primer set for 30 s and 72°C for 15 s) after the initial denaturation step (95°C for 10 min). Expression levels of the let-7 genes were based on the amount of the target message relative to the 5S rRNA control, to normalize the initial input of total RNA.

Hierarchical Clustering.
We used the Eisen CLUSTER and TREEVIEW programs for hierarchical clustering and visualization of data sets. Before applying the clustering algorithm, we log-transformed the fluorescence ratio for each expression and then average centered the data for all samples. Agglomerative hierarchical clustering was applied using the complete linkage method to investigate whether there was evidence for natural groupings of tumor samples based on correlations between gene-expression profiles.

Statistical Analysis.
The Kaplan-Meier method was used to estimate survival as a function of time, and survival differences were analyzed by the log-rank test. Cox regression analysis of factors potentially related to survival was performed to identify which independent factors might jointly have a significant influence on survival.

Colony Formation Assay.
The let-7 expression construct and a control plasmid were constructed by the cloning of annealed oligonucleotides of let-7a (sense, 5'-GATCCCCTGAGGTAGTAGGTTGTATAGTTTTT and antisense, 5'-AGCTAAAAACTATACAACCTACTACCTCAGGG), let-7f (sense, 5'-GATCCCCTGAGGTAGTAGATTGTATAGTTTTT and antisense, 5'-AGCTAAAAACTATACAATCTACTACCTCAGGG), or control (sense, 5'-GATCCCCTTTTTTTTGGAAA and antisense, 5'-AGCTTTTCCAAAAAAAAGGG) into pH1-RNApuro, in which expression of a gene is under the control of the RNA polymerase III H1-RNA gene promoter prepared by PCR amplification of human genomic DNA. The let-7a and -7f expression constructs were transfected into A549 lung adenocarcinoma cell line using the FuGENE 6 reagent (Roche, Inc. Basel, Switzerland) according to the manufacturer’s instructions. Cells were selected by the addition of puromycin (2 µg/ml) 3 days after the transfection and cultured at 37°C for 2 weeks. After 2 weeks of puromycin selection, the plates were stained with Giemsa and scored for the number of resistant colonies.


    Results
 Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
Reduced Expression of let-7 in Human Lung Cancers in Both in Vitro and in Vivo.
Northern blot analysis was first performed to analyze let-7 expression in 20 human lung cancer cell lines as well as in two immortalized human normal lung epithelial cell lines (Fig. 1A)Citation . The mature form of let-7 miRNA was readily detectable in both immortalized lung epithelial cell lines at a level comparable with that in normal lung tissues. In marked contrast, a significant reduction (>80%) in the expression levels of let-7 was observed in 60% (12 of 20) of lung cancer cell lines. Expression levels of let-7 in primary human lung cancer tissues taken directly from surgically treated patients, in which sufficient RNA were available, were further analyzed by Northern blot analysis. Consequently, 44% (7 of 16) of the cases examined were found to exhibit >80% reduction in let-7 expression when compared with that in the corresponding normal lung tissues (Fig. 1B)Citation . A more frequent occurrence of reduced let-7 expression in cell lines in vitro may be related to the inevitable contamination of normal stromal/inflammatory cells in tumor tissues in vivo or, alternatively, this may reflect in vitro selection of cells with reduced let-7 in the process of the establishment of cell lines. These findings thus clearly showed the frequent occurrence of a significant reduction in let-7 miRNA expression in lung cancers.



View larger version (40K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 1. Northern blot analysis of let-7 expression in primary lung cancers. A, representative Northern blot analysis in lung cancer cell lines in vitro. BEAS-2B and HPL1D, immortalized human normal bronchial and peripheral lung epithelial cell lines, respectively. HNLEC, human normal lung epithelial cell lines. B, representative Northern blot analysis of primary lung cancer specimens in vivo. 5S rRNA served as a loading control. N, normal lung; T, lung cancer.

 
Prognostic Impact of Reduced let-7 Expression in Surgically Treated Lung Cancer Patients.
We next wished to investigate whether reduced let-7 expression has any relation to clinicopathological characteristics of lung cancers in an isoform-specific manner. To this end, 143 lung cancer cases, which had undergone potential curative resection of NSCLCs, were examined by real-time reverse transcription-PCR analysis using let-7 isoforms-specific oligonucleotide primers. Expression levels of let-7 pri-miRNAs were consequently shown to vary significantly among lung cancer cases, although they tended to be coordinately regulated. The most abundant species were let-7a-1 and let-7f-1, which are known to be clustered within a few hundred bases in the human genome (6) and could be amplified together by reverse transcription-PCR (data not shown). We used unsupervised hierarchical clustering to classify the 143 resected human NSCLC cases in an unbiased manner without using any information on the identity of the samples. This procedure resulted in the classification of NSCLC cases into two major classes based on similarities in let-7 expression (Fig. 2A)Citation . Except for a significant association between cluster 1 with low let-7 expression and higher disease stages (P = 0.004 by the{lambda}2 test), no other significant associations were found between the clusters and various clinicopathological features including age, sex, histology, primary tumor status (pT), and differentiation grade. Of special interest was a striking difference in the postoperative survival of patients between the two clusters. The Kaplan-Meier survival curves demonstrated that patients belonging to cluster 1 were at a significantly greater risk of an earlier death than those classified as cluster 2 (P = 0.0003 by the log-rank test; Fig. 2BCitation ). A separate study analyzed the prognostic significance of let-7 in adenocarcinomas, which constitute the major proportion of lung cancers in Japan as well as in other countries such as the United States. We found that adenocarcinoma cases can also be divided into two major clusters, again showing that patients in cluster 1AD with low let-7 expression had significantly shorter survival than those in cluster 2AD with high let-7 expression (P = 0.03 by the log-rank test; Fig. 2, C and DCitation ).



View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 2. Hierarchical clustering and Kaplan-Meier survival curves based on expression of let-7 microRNA (miRNA) isoforms. A, results of unsupervised hierarchical clustering of the entire cohort of 143 nonsmall cell lung carcinoma (NSCLC) cases. B, Kaplan-Meier survival curves for NSCLC patients who were classified into clusters 1 and 2. The difference in postoperative survival between clusters 1 and 2 was highly significant (P = 0.0003 by log-rank test). C, results of unsupervised hierarchical clustering of the 105 adenocarcinoma cases. D, Kaplan-Meier survival curves for adenocarcinoma cases belonging to either cluster 1AD or 2AD. The difference in postoperative survival between clusters 1AD and 2AD was also statistically significant (P = 0.03 by log-rank test). Arrows and arrow heads, mixture of RNAs of 38 and 120 normal human peripheral lung tissues, respectively.

 
Univariate Cox regression analysis was then performed for the entire cohort and showed that, in addition to disease stage (P < 0.001; Table 1Citation ), classification into cluster 1 with characteristically low let-7 expression is a significant predictive factor for poor prognosis (P < 0.001). Cox proportional hazards modeling was then conducted to identify which independent factors would jointly have a significant influence on survival (Table 1)Citation . The inter-relationship of possible prognostic factors and survival was analyzed, using age, sex, histological type, smoking history, disease stage, and the let-7-defined cluster as variables, resulting in the identification of let-7-defined cluster as a significant, independent prognostic factor in surgically treated NSCLC patients after potentially curative resection (P = 0.009) in addition to disease stage (P < 0.001). The hazard ratio of earlier death was 2.17 (95% confidence interval, 1.21–3.89) for clusters 1 versus 2 and 3.49 (95% confidence interval, 1.89–6.42) for pathological stage II/III versus pathological stage I. Taken together, expression levels of let-7 seemed to have a significant impact on the postoperative survival of NSCLC patients.


View this table:
[in this window]
[in a new window]

 
Table 1 Cox regression analysis of various prognostic factors for postoperative survival of lung cancer patients

 
Growth Suppression of Lung Cancer Cells by Overexpression of Exogenous let-7.
The identification of a reduced expression of let-7 in lung cancers, in association with a shortened survival, prompted us to explore the possible biological significance of let-7 in lung cancer development. As an initial step, we introduced let-7 into a lung cancer cell line by using expression constructs, which were designed to synthesize mature miRNAs of two predominant let-7 isoforms, let-7a and let-7f, under the control of the RNA polymerase-III H1-RNA gene promoter. We confirmed that these expression constructs could work as expected using 293T cells (Fig. 3A)Citation . Overexpression of let-7f in A549 lung adenocarcinoma cell line resulted in a 78.6% reduction in the number of colonies, whereas the introduction of let-7a also showed similar but a more modest growth-inhibitory effect (Figs. 3, B and C)Citation . Similar results were obtained in five independent experiments, which were done in triplicate using three independent preparations of plasmid DNAs.



View larger version (31K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 3. Introduction of let-7 into A549 lung adenocarcinoma cell line. A, results of Northern blot analysis confirming expression of let-7a and let-7f isoforms. B, graphic presentation of a representative colony formation assay by the introduction of exogenous let-7. Similar results were obtained in five independent assays done in triplicate. C, representative dishes showing reduced colony formation by overexpression of exogenously introduced let-7.

 

    Discussion
 Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
It has become apparent that genomic information for transcribing miRNAs is indeed implemented in the human genome (6 , 9) , but extremely little information is available regarding their physiological and pathological roles. This is the first demonstration that expression levels of let-7 miRNA, which to date is one of the best-studied miRNAs, are altered in human lung cancers. Furthermore, we have shown that reduced let-7 expression is significantly associated with shortened postoperative survival and that overexpression of let-7 results in the inhibition of lung cancer cell growth. Altogether, these findings suggest that reduced expression of let-7 may play a role in the pathogenesis of lung cancers.

Very little information is available at the moment with regard to the potential pathological roles of miRNAs. Two proteins (Gemin 3 and Gemin 4), which are components of the protein complex related to spinal muscular atrophy, are also known to be components of a ribonucleoprotein complex containing miRNAs (microRNP; Ref. 9 ), whereas the Drosophila homologue of fragile X mental retardation protein has been shown to be a component of RNA-induced silencing complex/microRNPs (20 , 21) . This circumstantial evidence suggests the possibility of the involvement of miRNA machineries in these diseases. As for links between cancer and miRNA, Calin et al. (22) reported frequent down-regulation of miR15 and miR16 in chronic lymphocytic leukemia, whereas Michael et al. (23) recently reported reduced expression of miR-143 and miR-145 in human colon cancers. In contrast to these studies, which did not address the question of whether reduced expression of miRNAs has any influence on clinicopathological features, this study clearly shows that reduced let-7 expression is indeed significantly associated with the shortened survival of patients. Because no changes in let-7 expression were reported in colon cancers (23) , it is possible that miRNAs may be distinctly involved in the pathogenesis of these two most common cancers of adults and possibly in other types of human cancers.

It has been shown that the let-7 gene regulates developmental timing in C. elegans and that mutant worms lacking let-7 fail to properly execute a larval-to-adult switch in hypodermal cell development (13) . Although lin-41 is known to be post-transcriptionally repressed by let-7 (24) , it is not inconceivable that other genes may also be targeted by let-7, because of the requirement of imprecise base-pairing for miRNA-mediated translational repression (1) . Indeed, hbl-1/lin-57 was recently reported to be targeted by let-7 (14 , 15) , whereas a few additional genes have also been predicted to be a potential target for let-7 (24 , 25) . Interestingly, such potential targets include LIM kinase 2 (25) , which belongs to a gene family having a role in the regulation of cell shape and motility as well as possibly in metastasis. One could speculate that the change in miRNA expression as is seen in this study might be an efficient strategy for cancer cells to simultaneously alter the expression profile of a series of genes. Alterations in miRNA expression may accordingly confer cancer cells with selective growth advantage, allowing them to form a distant metastasis and resulting in the consequential death of the patient. This scheme may be consistent with the present finding of the significant prognostic impact of let-7 expression. One might argue that reduced expression of let-7 in lung cancers may merely reflect its oncofetal regulation, because fetal lung exhibited considerably lower let-7 expression than adult lung (data not shown). However, growth-inhibitory effects of overexpressed let-7 in A549 adenocarcinoma cell line argue against this possibility. Taken together, these findings suggest the potential involvement of reduction in let-7 expression in the pathogenesis of this fatal disease, although the results obtained with overexpression of mature miRNA need to be interpreted cautiously and await further experimental clarification.

In this study, we observed that various let-7 pri-miRNA isoforms were coordinately regulated, let-7a-1 and let-7f-1 being the most predominant. In this connection, it should be noted that some of the let-7 pri-miRNAs give rise to identical mature miRNA isoforms, and the others may also have presumably very similar, if not identical, spectra of the target genes (6) . It is uncertain at the moment how the expression levels of various let-7 isoforms are coordinated, and this remains an intriguing question awaiting further investigation.

In conclusion, we have shown for the first time that let-7 expression is frequently reduced in lung cancers and that alterations in the miRNA expression may have a prognostic impact on the survival of surgically treated lung cancer patients. These findings warrant additional studies to investigate whether let-7 alterations are also involved in other types of human cancers and how altered miRNA expression would manifest the biological and biochemical consequences in the development of human cancers. Accordingly, future identification of the downstream targets for let-7 may provide clues to develop a novel therapeutic means. It is envisaged that such future studies may ultimately provide a foundation for a new paradigm of the involvement of noncoding small RNA species, miRNA, in human oncogenesis.


    FOOTNOTES
 
Grant support: This work was supported in part by a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan, a Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science, and a Grant-in-Aid for the Second Term Comprehensive Ten-Year Strategy for Cancer Control from the Ministry of Health and Welfare, Japan.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: J. Takamizawa and H. Konishi contributed equally to the present study. H. Konishi is currently at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.

Requests for reprints: Takashi Takahashi, Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan. Phone: 81-52-764-2983; Fax: 81-52-764-2983; E-mail: tak{at}aichi-cc.jp

Received 2/21/04. Revised 4/ 9/04. Accepted 4/19/04.


    REFERENCES
 Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell, 113: 673-6, 2003.[CrossRef][Medline]
  2. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science (Wash D C), 293: 834-8, 2001.
  3. Grishok A, Pasquinelli AE, Conte D, et al Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell, 106: 23-34, 2001.[CrossRef][Medline]
  4. Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev, 15: 2654-9, 2001.[Abstract/Free Full Text]
  5. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J, 21: 4663-70, 2002.[CrossRef][Medline]
  6. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science (Wash D C), 294: 853-8, 2001.
  7. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science (Wash D C), 294: 858-62, 2001.
  8. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science (Wash D C), 294: 862-4, 2001.
  9. Mourelatos Z, Dostie J, Paushkin S, et al miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev, 16: 720-8, 2002.[Abstract/Free Full Text]
  10. Lim LP, Glasner ME, Yekta S, Burge CB, Bartel DP. Vertebrate microRNA genes. Science (Wash D C), 299: 1540 2003.
  11. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75: 843-54, 1993.[CrossRef][Medline]
  12. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell, 75: 855-62, 1993.[CrossRef][Medline]
  13. Reinhart BJ, Slack FJ, Basson M, et al The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature (Lond), 403: 901-6, 2000.[CrossRef][Medline]
  14. Abrahante JE, Daul AL, Li M, et al The Caenorhabditis elegans hunchback-like gene lin-57/hbl-1 controls developmental time and is regulated by microRNAs. Dev Cell, 4: 625-37, 2003.[CrossRef][Medline]
  15. Lin SY, Johnson SM, Abraham M, et al The C elegans hunchback homolog, hbl-1, controls temporal patterning and is a probable microRNA target. Dev Cell, 4: 639-50, 2003.[CrossRef][Medline]
  16. Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell, 113: 25-36, 2003.[CrossRef][Medline]
  17. Xu P, Vernooy SY, Guo M, Hay BA. The Drosophila MicroRNA Mir-14 Suppresses Cell Death and Is Required for Normal Fat Metabolism. Curr Biol, 13: 790-5, 2003.[CrossRef][Medline]
  18. Pasquinelli AE, Reinhart BJ, Slack F, et al Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature (Lond), 408: 86-9, 2000.[CrossRef][Medline]
  19. Masuda A, Kondo M, Saito T, et al Establishment of human peripheral lung epithelial cell lines (HPL1) retaining differentiated characteristics and responsiveness to epidermal growth factor, hepatocyte growth factor, and transforming growth factor ß1. Cancer Res, 57: 4898-904, 1997.[Abstract/Free Full Text]
  20. Caudy AA, Myers M, Hannon GJ, Hammond SM. Fragile X-related protein and VIG associate with the RNA interference machinery. Genes Dev, 16: 2491-6, 2002.[Abstract/Free Full Text]
  21. Ishizuka A, Siomi MC, Siomi H. A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins. Genes Dev, 16: 2497-508, 2002.[Abstract/Free Full Text]
  22. Calin GA, Dumitru CD, Shimizu M, et al Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA, 99: 15524-9, 2002.[Abstract/Free Full Text]
  23. Michael MZ, O’Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res, 1: 882-91, 2003.[Abstract/Free Full Text]
  24. Slack FJ, Basson M, Liu Z, Ambros V, Horvitz HR, Ruvkun G. The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-7 regulatory RNA and the LIN-29 transcription factor. Mol Cell, 5: 659-69, 2000.[CrossRef][Medline]
  25. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell, 115: 787-98, 2003.[CrossRef][Medline]



This article has been cited by other articles:


Home page
BloodHome page
A. Kotani, D. Ha, J. Hsieh, P. K. Rao, D. Schotte, M. L. den Boer, S. A. Armstrong, and H. F. Lodish
miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221
Blood, November 5, 2009; 114(19): 4169 - 4178.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
S.-W. Guo
Epigenetics of endometriosis
Mol. Hum. Reprod., October 1, 2009; 15(10): 587 - 607.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. A. Mathe, G. H. Nguyen, E. D. Bowman, Y. Zhao, A. Budhu, A. J. Schetter, R. Braun, M. Reimers, K. Kumamoto, D. Hughes, et al.
MicroRNA Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus: Associations with Survival
Clin. Cancer Res., October 1, 2009; 15(19): 6192 - 6200.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. R. Epis, K. M. Giles, A. Barker, T. S. Kendrick, and P. J. Leedman
miR-331-3p Regulates ERBB-2 Expression and Androgen Receptor Signaling in Prostate Cancer
J. Biol. Chem., September 11, 2009; 284(37): 24696 - 24704.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
Z. Ma, W.-O. Lui, A. Fire, and S. S. Dadras
Profiling and Discovery of Novel miRNAs from Formalin-Fixed, Paraffin-Embedded Melanoma and Nodal Specimens
J. Mol. Diagn., September 1, 2009; 11(5): 420 - 429.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Li, T. G. VandenBoom II, D. Kong, Z. Wang, S. Ali, P. A. Philip, and F. H. Sarkar
Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells
Cancer Res., August 15, 2009; 69(16): 6704 - 6712.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
S. Ocak, M. L. Sos, R. K. Thomas, and P. P. Massion
High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications
Eur. Respir. J., August 1, 2009; 34(2): 489 - 506.
[Abstract] [Full Text] [PDF]


Home page
RNAHome page
G. Sotiropoulou, G. Pampalakis, E. Lianidou, and Z. Mourelatos
Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell
RNA, August 1, 2009; 15(8): 1443 - 1461.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Seike, A. Goto, T. Okano, E. D. Bowman, A. J. Schetter, I. Horikawa, E. A. Mathe, J. Jen, P. Yang, H. Sugimura, et al.
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers
PNAS, July 21, 2009; 106(29): 12085 - 12090.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. E. Hoffman, T. Zheng, C. Yi, D. Leaderer, J. Weidhaas, F. Slack, Y. Zhang, T. Paranjape, and Y. Zhu
microRNA miR-196a-2 and Breast Cancer: A Genetic and Epigenetic Association Study and Functional Analysis
Cancer Res., July 15, 2009; 69(14): 5970 - 5977.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Raponi, L. Dossey, T. Jatkoe, X. Wu, G. Chen, H. Fan, and D. G. Beer
MicroRNA Classifiers for Predicting Prognosis of Squamous Cell Lung Cancer
Cancer Res., July 15, 2009; 69(14): 5776 - 5783.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S. Sakamoto, K. Aoki, T. Higuchi, H. Todaka, K. Morisawa, N. Tamaki, E. Hatano, A. Fukushima, T. Taniguchi, and Y. Agata
The NF90-NF45 Complex Functions as a Negative Regulator in the MicroRNA Processing Pathway
Mol. Cell. Biol., July 1, 2009; 29(13): 3754 - 3769.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Bandi, S. Zbinden, M. Gugger, M. Arnold, V. Kocher, L. Hasan, A. Kappeler, T. Brunner, and E. Vassella
miR-15a and miR-16 Are Implicated in Cell Cycle Regulation in a Rb-Dependent Manner and Are Frequently Deleted or Down-regulated in Non-Small Cell Lung Cancer
Cancer Res., July 1, 2009; 69(13): 5553 - 5559.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
A. V. Antonov, S. Dietmann, P. Wong, D. Lutter, and H. W. Mewes
GeneSet2miRNA: finding the signature of cooperative miRNA activities in the gene lists
Nucleic Acids Res., July 1, 2009; 37(suppl_2): W323 - W328.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. Ueda, G. Kohanbash, K. Sasaki, M. Fujita, X. Zhu, E. R. Kastenhuber, H. A. McDonald, D. M. Potter, R. L. Hamilton, M. T. Lotze, et al.
Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1
PNAS, June 30, 2009; 106(26): 10746 - 10751.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Li, H. Huang, L. Sun, M. Yang, C. Pan, W. Chen, D. Wu, Z. Lin, C. Zeng, Y. Yao, et al.
MiR-21 Indicates Poor Prognosis in Tongue Squamous Cell Carcinomas as an Apoptosis Inhibitor
Clin. Cancer Res., June 15, 2009; 15(12): 3998 - 4008.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
E. Brambilla and A. Gazdar
Pathogenesis of lung cancer signalling pathways: roadmap for therapies
Eur. Respir. J., June 1, 2009; 33(6): 1485 - 1497.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
A. Oulas, A. Boutla, K. Gkirtzou, M. Reczko, K. Kalantidis, and P. Poirazi
Prediction of novel microRNA genes in cancer-associated genomic regions--a combined computational and experimental approach
Nucleic Acids Res., June 1, 2009; 37(10): 3276 - 3287.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
M. Bhaskaran, Y. Wang, H. Zhang, T. Weng, P. Baviskar, Y. Guo, D. Gou, and L. Liu
MicroRNA-127 modulates fetal lung development
Physiol Genomics, May 13, 2009; 37(3): 268 - 278.
[Abstract] [Full Text] [PDF]


Home page
Cancer Genomics ProteomicsHome page
X. LIU, J. YU, L. JIANG, A. WANG, F. SHI, H. YE, and X. ZHOU
MicroRNA-222 Regulates Cell Invasion by Targeting Matrix Metalloproteinase 1 (MMP1) and Manganese Superoxide Dismutase 2 (SOD2) in Tongue Squamous Cell Carcinoma Cell Lines
Cancer Genomics Proteomics, May 1, 2009; 6(3): 131 - 139.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
A. C. Kim, F. M. Barlaskar, J. H. Heaton, T. Else, V. R. Kelly, K. T. Krill, J. O. Scheys, D. P. Simon, A. Trovato, W.-H. Yang, et al.
In Search of Adrenocortical Stem and Progenitor Cells
Endocr. Rev., May 1, 2009; 30(3): 241 - 263.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
S M Khoshnaw, A R Green, D G Powe, and I O Ellis
MicroRNA involvement in the pathogenesis and management of breast cancer
J. Clin. Pathol., May 1, 2009; 62(5): 422 - 428.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. Moriyama, K. Ohuchida, K. Mizumoto, J. Yu, N. Sato, T. Nabae, S. Takahata, H. Toma, E. Nagai, and M. Tanaka
MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance
Mol. Cancer Ther., May 1, 2009; 8(5): 1067 - 1074.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
T. Tian, Y. Shu, J. Chen, Z. Hu, L. Xu, G. Jin, J. Liang, P. Liu, X. Zhou, R. Miao, et al.
A Functional Genetic Variant in microRNA-196a2 Is Associated with Increased Susceptibility of Lung Cancer in Chinese
Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1183 - 1187.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Hiyoshi, H. Kamohara, R. Karashima, N. Sato, Y. Imamura, Y. Nagai, N. Yoshida, E. Toyama, N. Hayashi, M. Watanabe, et al.
MicroRNA-21 Regulates the Proliferation and Invasion in Esophageal Squamous Cell Carcinoma
Clin. Cancer Res., March 15, 2009; 15(6): 1915 - 1922.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Legesse-Miller, O. Elemento, S. J. Pfau, J. J. Forman, S. Tavazoie, and H. A. Coller
let-7 Overexpression Leads to an Increased Fraction of Cells in G2/M, Direct Down-regulation of Cdc34, and Stabilization of Wee1 Kinase in Primary Fibroblasts
J. Biol. Chem., March 13, 2009; 284(11): 6605 - 6609.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T.-C. Chang, L. R. Zeitels, H.-W. Hwang, R. R. Chivukula, E. A. Wentzel, M. Dews, J. Jung, P. Gao, C. V. Dang, M. A. Beer, et al.
Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation
PNAS, March 3, 2009; 106(9): 3384 - 3389.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S. Watanabe, Y. Ueda, S.-i. Akaboshi, Y. Hino, Y. Sekita, and M. Nakao
HMGA2 Maintains Oncogenic RAS-Induced Epithelial-Mesenchymal Transition in Human Pancreatic Cancer Cells
Am. J. Pathol., March 1, 2009; 174(3): 854 - 868.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. Wu, S. Zhu, Y. Ding, W. T. Beck, and Y.-Y. Mo
MicroRNA-mediated Regulation of Ubc9 Expression in Cancer Cells
Clin. Cancer Res., March 1, 2009; 15(5): 1550 - 1557.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. J. Webster, K. M. Giles, K. J. Price, P. M. Zhang, J. S. Mattick, and P. J. Leedman
Regulation of Epidermal Growth Factor Receptor Signaling in Human Cancer Cells by MicroRNA-7
J. Biol. Chem., February 27, 2009; 284(9): 5731 - 5741.
[Abstract] [Full Text] [PDF]


Home page
BioinformaticsHome page
F. Xin, M. Li, C. Balch, M. Thomson, M. Fan, Y. Liu, S. M. Hammond, S. Kim, and K. P. Nephew
Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance
Bioinformatics, February 15, 2009; 25(4): 430 - 434.
[Abstract] [Full Text] [PDF]


Home page
Cold Spring Harb Symp Quant BiolHome page
G.Q. Daley
Common Themes of Dedifferentiation in Somatic Cell Reprogramming and Cancer
Cold Spring Harb Symp Quant Biol, January 15, 2009; (2009) sqb.2008.73.041v1.
[Abstract] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
S. P. Nana-Sinkam, M. G. Hunter, G. J. Nuovo, T. D. Schmittgen, R. Gelinas, D. Galas, and C. B. Marsh
Integrating the MicroRNome into the Study of Lung Disease
Am. J. Respir. Crit. Care Med., January 1, 2009; 179(1): 4 - 10.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
F. J. Slack and J. B. Weidhaas
MicroRNA in Cancer Prognosis
N. Engl. J. Med., December 18, 2008; 359(25): 2720 - 2722.
[Full Text] [PDF]


Home page
Cancer Res.Home page
S. A. Georges, M. C. Biery, S.-y. Kim, J. M. Schelter, J. Guo, A. N. Chang, A. L. Jackson, M. O. Carleton, P. S. Linsley, M. A. Cleary, et al.
Coordinated Regulation of Cell Cycle Transcripts by p53-Inducible microRNAs, miR-192 and miR-215
Cancer Res., December 15, 2008; 68(24): 10105 - 10112.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Yang, S. Kaur, S. Volinia, J. Greshock, H. Lassus, K. Hasegawa, S. Liang, A. Leminen, S. Deng, L. Smith, et al.
MicroRNA Microarray Identifies Let-7i as a Novel Biomarker and Therapeutic Target in Human Epithelial Ovarian Cancer
Cancer Res., December 15, 2008; 68(24): 10307 - 10314.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
X. Agirre, A. Jimenez-Velasco, E. San Jose-Eneriz, L. Garate, E. Bandres, L. Cordeu, O. Aparicio, B. Saez, G. Navarro, A. Vilas-Zornoza, et al.
Down-Regulation of hsa-miR-10a in Chronic Myeloid Leukemia CD34+ Cells Increases USF2-Mediated Cell Growth
Mol. Cancer Res., December 1, 2008; 6(12): 1830 - 1840.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S. Kalscheuer, X. Zhang, Y. Zeng, and P. Upadhyaya
Differential expression of microRNAs in early-stage neoplastic transformation in the lungs of F344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
Carcinogenesis, December 1, 2008; 29(12): 2394 - 2399.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. W. Nasser, J. Datta, G. Nuovo, H. Kutay, T. Motiwala, S. Majumder, B. Wang, S. Suster, S. T. Jacob, and K. Ghoshal
Down-regulation of Micro-RNA-1 (miR-1) in Lung Cancer: SUPPRESSION OF TUMORIGENIC PROPERTY OF LUNG CANCER CELLS AND THEIR SENSITIZATION TO DOXORUBICIN-INDUCED APOPTOSIS BY miR-1
J. Biol. Chem., November 28, 2008; 283(48): 33394 - 33405.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. L. Yeung, J.-i. Yasunaga, Y. Bennasser, N. Dusetti, D. Harris, N. Ahmad, M. Matsuoka, and K.-T. Jeang
Roles for MicroRNAs, miR-93 and miR-130b, and Tumor Protein 53-Induced Nuclear Protein 1 Tumor Suppressor in Cell Growth Dysregulation by Human T-Cell Lymphotrophic Virus 1
Cancer Res., November 1, 2008; 68(21): 8976 - 8985.
[Abstract] [Full Text] [PDF]


Home page
RNAHome page
L.-X. Yan, X.-F. Huang, Q. Shao, M.-Y. Huang, L. Deng, Q.-L. Wu, Y.-X. Zeng, and J.-Y. Shao
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis
RNA, November 1, 2008; 14(11): 2348 - 2360.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S. Tokumaru, M. Suzuki, H. Yamada, M. Nagino, and T. Takahashi
let-7 regulates Dicer expression and constitutes a negative feedback loop
Carcinogenesis, November 1, 2008; 29(11): 2073 - 2077.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. J. Chin, E. Ratner, S. Leng, R. Zhai, S. Nallur, I. Babar, R.-U. Muller, E. Straka, L. Su, E. A. Burki, et al.
A SNP in a let-7 microRNA Complementary Site in the KRAS 3' Untranslated Region Increases Non-Small Cell Lung Cancer Risk
Cancer Res., October 15, 2008; 68(20): 8535 - 8540.
[Abstract] [Full Text] [PDF]


Home page
RNAHome page
S.-P. Chan, G. Ramaswamy, E.-Y. Choi, and F. J. Slack
Identification of specific let-7 microRNA binding complexes in Caenorhabditis elegans
RNA, October 1, 2008; 14(10): 2104 - 2114.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
A. Markou, E. G. Tsaroucha, L. Kaklamanis, M. Fotinou, V. Georgoulias, and E. S. Lianidou
Prognostic Value of Mature MicroRNA-21 and MicroRNA-205 Overexpression in Non-Small Cell Lung Cancer by Quantitative Real-Time RT-PCR
Clin. Chem., October 1, 2008; 54(10): 1696 - 1704.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Yamakuchi, M. Ferlito, and C. J. Lowenstein
miR-34a repression of SIRT1 regulates apoptosis
PNAS, September 9, 2008; 105(36): 13421 - 13426.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Wu, N. Jolicoeur, Z. Li, L. Zhang, Y. Fortin, D. L'Abbe, Z. Yu, and S.-H. Shen
Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs
Carcinogenesis, September 1, 2008; 29(9): 1710 - 1716.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
W. Tam
The Emergent Role of MicroRNAs in Molecular Diagnostics of Cancer
J. Mol. Diagn., September 1, 2008; 10(5): 411 - 414.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
Z. Yu, C. Wang, M. Wang, Z. Li, M. C. Casimiro, M. Liu, K. Wu, J. Whittle, X. Ju, T. Hyslop, et al.
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation
J. Cell Biol., August 11, 2008; 182(3): 509 - 517.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Piskounova, S. R. Viswanathan, M. Janas, R. J. LaPierre, G. Q. Daley, P. Sliz, and R. I. Gregory
Determinants of MicroRNA Processing Inhibition by the Developmentally Regulated RNA-binding Protein Lin28
J. Biol. Chem., August 1, 2008; 283(31): 21310 - 21314.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Taguchi, K. Yanagisawa, M. Tanaka, K. Cao, Y. Matsuyama, H. Goto, and T. Takahashi
Identification of Hypoxia-Inducible Factor-1{alpha} as a Novel Target for miR-17-92 MicroRNA Cluster
Cancer Res., July 15, 2008; 68(14): 5540 - 5545.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Jongen-Lavrencic, S. M. Sun, M. K. Dijkstra, P. J. M. Valk, and B. Lowenberg
MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia
Blood, May 15, 2008; 111(10): 5078 - 5085.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Wang, A. T. C. Lee, J. Z. I. Ma, J. Wang, J. Ren, Y. Yang, E. Tantoso, K.-B. Li, L. L. P. J Ooi, P. Tan, et al.
Profiling MicroRNA Expression in Hepatocellular Carcinoma Reveals MicroRNA-224 Up-regulation and Apoptosis Inhibitor-5 as a MicroRNA-224-specific Target
J. Biol. Chem., May 9, 2008; 283(19): 13205 - 13215.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J.-W. Lee, C. H. Choi, J.-J. Choi, Y.-A. Park, S.-J. Kim, S. Y. Hwang, W. Y. Kim, T.-J. Kim, J.-H. Lee, B.-G. Kim, et al.
Altered MicroRNA Expression in Cervical Carcinomas
Clin. Cancer Res., May 1, 2008; 14(9): 2535 - 2542.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. J. Nam, H. Yoon, S. W. Kim, H. Kim, Y. T. Kim, J. H. Kim, J. W. Kim, and S. Kim
MicroRNA Expression Profiles in Serous Ovarian Carcinoma
Clin. Cancer Res., May 1, 2008; 14(9): 2690 - 2695.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Sengupta, J. A. den Boon, I-H. Chen, M. A. Newton, S. A. Stanhope, Y.-J. Cheng, C.-J. Chen, A. Hildesheim, B. Sugden, and P. Ahlquist
MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins
PNAS, April 15, 2008; 105(15): 5874 - 5878.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Motoyama, H. Inoue, Y. Nakamura, H. Uetake, K. Sugihara, and M. Mori
Clinical Significance of High Mobility Group A2 in Human Gastric Cancer and Its Relationship to let-7 MicroRNA Family
Clin. Cancer Res., April 15, 2008; 14(8): 2334 - 2340.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
G. A. Calin and C. M. Croce
MicroRNA-Cancer Connection: The Beginning of a New Tale
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 667 - 675.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
S.-M. Park, A. B. Gaur, E. Lengyel, and M. E. Peter
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2
Genes & Dev., April 1, 2008; 22(7): 894 - 907.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
Y. Peng, J. Laser, G. Shi, K. Mittal, J. Melamed, P. Lee, and J.-J. Wei
Antiproliferative Effects by Let-7 Repression of High-Mobility Group A2 in Uterine Leiomyoma
Mol. Cancer Res., April 1, 2008; 6(4): 663 - 673.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. S. Kumar, S. J. Erkeland, R. E. Pester, C. Y. Chen, M. S. Ebert, P. A. Sharp, and T. Jacks
Suppression of non-small cell lung tumor development by the let-7 microRNA family
PNAS, March 11, 2008; 105(10): 3903 - 3908.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
D. Landi, F. Gemignani, A. Naccarati, B. Pardini, P. Vodicka, L. Vodickova, J. Novotny, A. Forsti, K. Hemminki, F. Canzian, et al.
Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer
Carcinogenesis, March 1, 2008; 29(3): 579 - 584.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
K. Huppi, N. Volfovsky, T. Runfola, T. L. Jones, M. Mackiewicz, S. E. Martin, J. F. Mushinski, R. Stephens, and N. J. Caplen
The Identification of MicroRNAs in a Genomically Unstable Region of Human Chromosome 8q24
Mol. Cancer Res., February 1, 2008; 6(2): 212 - 221.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Yang, W. Kong, L. He, J.-J. Zhao, J. D. O'Donnell, J. Wang, R. M. Wenham, D. Coppola, P. A. Kruk, S. V. Nicosia, et al.
MicroRNA Expression Profiling in Human Ovarian Cancer: miR-214 Induces Cell Survival and Cisplatin Resistance by Targeting PTEN
Cancer Res., January 15, 2008; 68(2): 425 - 433.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Jiang, Y. Gusev, I. Aderca, T. A. Mettler, D. M. Nagorney, D. J. Brackett, L. R. Roberts, and T. D. Schmittgen
Association of MicroRNA Expression in Hepatocellular Carcinomas with Hepatitis Infection, Cirrhosis, and Patient Survival
Clin. Cancer Res., January 15, 2008; 14(2): 419 - 427.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Guo, Z. Chen, L. Zhang, F. Zhou, S. Shi, X. Feng, B. Li, X. Meng, X. Ma, M. Luo, et al.
Distinctive MicroRNA Profiles Relating to Patient Survival in Esophageal Squamous Cell Carcinoma
Cancer Res., January 1, 2008; 68(1): 26 - 33.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. B. Weidhaas, I. Babar, S. M. Nallur, P. Trang, S. Roush, M. Boehm, E. Gillespie, and F. J. Slack
MicroRNAs as Potential Agents to Alter Resistance to Cytotoxic Anticancer Therapy
Cancer Res., December 1, 2007; 67(23): 11111 - 11116.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Ovcharenko, K. Kelnar, C. Johnson, N. Leng, and D. Brown
Genome-Scale MicroRNA and Small Interfering RNA Screens Identify Small RNA Modulators of TRAIL-Induced Apoptosis Pathway
Cancer Res., November 15, 2007; 67(22): 10782 - 10788.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. U. Mertens-Talcott, S. Chintharlapalli, X. Li, and S. Safe
The Oncogenic microRNA-27a Targets Genes That Regulate Specificity Protein Transcription Factors and the G2-M Checkpoint in MDA-MB-231 Breast Cancer Cells
Cancer Res., November 15, 2007; 67(22): 11001 - 11011.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Lu, D. Katsaros, I. A. Rigault de la Longrais, O. Sochirca, and H. Yu
Hypermethylation of let-7a-3 in Epithelial Ovarian Cancer Is Associated with Low Insulin-like Growth Factor-II Expression and Favorable Prognosis
Cancer Res., November 1, 2007; 67(21): 10117 - 10122.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J.-W. Cui, Y.-J. Li, A. Sarkar, J. Brown, Y.-H. Tan, M. Premyslova, C. Michaud, N. Iscove, G.-J. Wang, and Y. Ben-David
Retroviral insertional activation of the Fli-3 locus in erythroleukemias encoding a cluster of microRNAs that convert Epo-induced differentiation to proliferation
Blood, October 1, 2007; 110(7): 2631 - 2640.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
M. Kruhoffer, L. Dyrskjot, T. Voss, R. L.P. Lindberg, R. Wyrich, T. Thykjaer, and T. F. Orntoft
Isolation of Microarray-Grade Total RNA, MicroRNA, and DNA from a Single PAXgene Blood RNA Tube
J. Mol. Diagn., September 1, 2007; 9(4): 452 - 458.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
W. Zhang, J. E. Dahlberg, and W. Tam
MicroRNAs in Tumorigenesis: A Primer
Am. J. Pathol., September 1, 2007; 171(3): 728 - 738.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. D. Johnson, A. Esquela-Kerscher, G. Stefani, M. Byrom, K. Kelnar, D. Ovcharenko, M. Wilson, X. Wang, J. Shelton, J. Shingara, et al.
The let-7 MicroRNA Represses Cell Proliferation Pathways in Human Cells
Cancer Res., August 15, 2007; 67(16): 7713 - 7722.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Galardi, N. Mercatelli, E. Giorda, S. Massalini, G. V. Frajese, S. A. Ciafre, and M. G. Farace
miR-221 and miR-222 Expression Affects the Proliferation Potential of Human Prostate Carcinoma Cell Lines by Targeting p27Kip1
J. Biol. Chem., August 10, 2007; 282(32): 23716 - 23724.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
Z. Yu, Z. Li, N. Jolicoeur, L. Zhang, Y. Fortin, E. Wang, M. Wu, and S.-H. Shen
Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers
Nucleic Acids Res., July 26, 2007; 35(13): 4535 - 4541.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Shell, S.-M. Park, A. R. Radjabi, R. Schickel, E. O. Kistner, D. A. Jewell, C. Feig, E. Lengyel, and M. E. Peter
Let-7 expression defines two differentiation stages of cancer
PNAS, July 3, 2007; 104(27): 11400 - 11405.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
W.-O. Lui, N. Pourmand, B. K. Patterson, and A. Fire
Patterns of Known and Novel Small RNAs in Human Cervical Cancer
Cancer Res., July 1, 2007; 67(13): 6031 - 6043.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Gramantieri, M. Ferracin, F. Fornari, A. Veronese, S. Sabbioni, C.-G. Liu, G. A. Calin, C. Giovannini, E. Ferrazzi, G. L. Grazi, et al.
Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma
Cancer Res., July 1, 2007; 67(13): 6092 - 6099.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. P. Porkka, M. J. Pfeiffer, K. K. Waltering, R. L. Vessella, T. L.J. Tammela, and T. Visakorpi
MicroRNA Expression Profiling in Prostate Cancer
Cancer Res., July 1, 2007; 67(13): 6130 - 6135.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Landais, S. Landry, P. Legault, and E. Rassart
Oncogenic Potential of the miR-106-363 Cluster and Its Implication in Human T-Cell Leukemia
Cancer Res., June 15, 2007; 67(12): 5699 - 5707.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
Y. M. Shah, K. Morimura, Q. Yang, T. Tanabe, M. Takagi, and F. J. Gonzalez
Peroxisome Proliferator-Activated Receptor {alpha} Regulates a MicroRNA-Mediated Signaling Cascade Responsible for Hepatocellular Proliferation
Mol. Cell. Biol., June 15, 2007; 27(12): 4238 - 4247.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
M. Negrini, M. Ferracin, S. Sabbioni, and C. M. Croce
MicroRNAs in human cancer: from research to therapy
J. Cell Sci., June 1, 2007; 120(11): 1833 - 1840.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Zhu, M.-L. Si, H. Wu, and Y.-Y. Mo
MicroRNA-21 Targets the Tumor Suppressor Gene Tropomyosin 1 (TPM1)
J. Biol. Chem., May 11, 2007; 282(19): 14328 - 14336.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Sevignani, G. A. Calin, S. C. Nnadi, M. Shimizu, R. V. Davuluri, T. Hyslop, P. Demant, C. M. Croce, and L. D. Siracusa
MicroRNA genes are frequently located near mouse cancer susceptibility loci
PNAS, May 8, 2007; 104(19): 8017 - 8022.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
A. R.J. Young and M. Narita
Oncogenic HMGA2: short or small?
Genes & Dev., May 1, 2007; 21(9): 1005 - 1009.
[Full Text] [PDF]


Home page
Genes Dev.Home page
Y. S. Lee and A. Dutta
The tumor suppressor microRNA let-7 represses the HMGA2 oncogene
Genes & Dev., May 1, 2007; 21(9): 1025 - 1030.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. Zhou, S. Wang, C. Mayr, D. P. Bartel, and H. F. Lodish
miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely
PNAS, April 24, 2007; 104(17): 7080 - 7085.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
N. Yanaihara, M. Seike, A. Schetter, C.M. Croce, and C.C. Harris
MicroRNA Molecular Profiles in Cancer Diagnosis and Prognosis
Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 125 - 126.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Meng, R. Henson, H. Wehbe-Janek, H. Smith, Y. Ueno, and T. Patel
The MicroRNA let-7a Modulates Interleukin-6-dependent STAT-3 Survival Signaling in Malignant Human Cholangiocytes
J. Biol. Chem., March 16, 2007; 282(11): 8256 - 8264.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
C. Mayr, M. T. Hemann, and D. P. Bartel
Disrupting the Pairing Between let-7 and Hmga2 Enhances Oncogenic Transformation
Science, March 16, 2007; 315(5818): 1576 - 1579.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Brueckner, C. Stresemann, R. Kuner, C. Mund, T. Musch, M. Meister, H. Sultmann, and F. Lyko
The Human let-7a-3 Locus Contains an Epigenetically Regulated MicroRNA Gene with Oncogenic Function
Cancer Res., February 15, 2007; 67(4): 1419 - 1423.
[Abstract] [Full Text] [PDF]


Home page
BioinformaticsHome page
N. Yosef, Z. Yakhini, A. Tsalenko, V. Kristensen, A.-L. Borresen-Dale, E. Ruppin, and R. Sharan
A supervised approach for identifying discriminating genotype patterns and its application to breast cancer data
Bioinformatics, January 15, 2007; 23(2): e91 - e98.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
K. V. Prasanth and D. L. Spector
Eukaryotic regulatory RNAs: an answer to the 'genome complexity' conundrum
Genes & Dev., January 1, 2007; 21(1): 11 - 42.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
H. Osada and T. Takahashi
MicroRNAs in biological processes and carcinogenesis
Carcinogenesis, January 1, 2007; 28(1): 2 - 12.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. Sugito, H. Ishiguro, Y. Kuwabara, M. Kimura, A. Mitsui, H. Kurehara, T. Ando, R. Mori, N. Takashima, R. Ogawa, et al.
RNASEN Regulates Cell Proliferation and Affects Survival in Esophageal Cancer Patients
Clin. Cancer Res., December 15, 2006; 12(24): 7322 - 7328.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takamizawa, J.
Right arrow Articles by Takahashi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takamizawa, J.
Right arrow Articles by Takahashi, T.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online